Journalists Discuss Cracks in the Health Care System and Roadblocks to Covid Booster Shots
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Drugs
421 - 440 of 1,303 Results
-
-
‘Somebody Is Gonna Die’: Medi-Cal Patients Struggle to Fill Prescriptions
Problems with California’s new Medicaid prescription drug program are preventing thousands of patients from getting their medications, including some life-saving ones. State officials say they’re working on fixes.
-
Pharmacies Are Turning Away Immunocompromised Patients Seeking 4th Covid Shot
The Centers for Disease Control and Prevention quietly changed its guidance to allow an extra shot in certain cases, but some pharmacy personnel are confused about who is eligible.
By Liz Szabo -
I Write About America’s Absurd Health Care System. Then I Got Caught Up in It.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
-
Patient, Beware: Some States Still Pushing Ineffective Covid Antibody Treatments
The top 12 states using antibody therapies produced by Regeneron and Lilly — which research shows don’t work against the omicron variant — include several Southern states with some of the nation’s lowest vaccination rates, but also California, which ranks among the top 20 for fully vaccinated residents.
-
As Omicron Surges, Effort to Vaccinate Young Children Stalls
Just 18% of 5- to 11-year-olds are fully vaccinated, with rates varying significantly across the country, a KHN analysis of federal data shows. Pediatricians say the slow pace and geographic disparities are alarming, especially against the backdrop of record numbers of cases and pediatric hospitalizations.
By Rachana Pradhan and Hannah Recht -
KHN’s ‘What the Health?’: Dealing With Drug Prices
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
-
Clinics Say State’s New Medicaid Drug Program Will Force Them to Cut Services
On Jan. 1, California started buying prescription drugs for its nearly 14 million Medicaid enrollees, a responsibility that had primarily been held by managed-care insurance plans. State officials estimate California will save hundreds of millions of dollars by flexing its purchasing power, but some health clinics expect to lose money.
-
Deep Roots Help This Chicago Pharmacist Avoid Creating Another Drugstore Desert
Predominantly Black and Hispanic urban areas are more likely than white neighborhoods to see local pharmacies close and are more likely to be pharmacy deserts. In Chicago, one pharmacist is bucking the trend, operating the drugstore his father opened in the 1960s in a Black neighborhood.
-
KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden’s domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation’s health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
-
Local Pharmacists Fill Rx Void as Big Brands Pull Out of Rural Areas
Stores like Walmart and Shopko opened pharmacies in small towns, either buying out the local pharmacy or driving it out of business. What happens when those chains later withdraw, leaving communities with no pharmacy?
-
Seeking Refills: Aging Pharmacists Leave Drugstores Vacant in Rural America
Independent pharmacists who want to retire often have trouble attracting new pharmacists to take over their practices, particularly in rural areas. That can cause smaller towns to lose their pharmacies. With many pharmacists near retirement, the problem may only get worse.
-
KHN’s ‘What the Health?’: Oh, Oh, Omicron
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
With Overdose Deaths Surging, Advocates on the Ground Push for Over-the-Counter Naloxone
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
-
Texas Toughens Ban on Medication-by-Mail Abortions With Jail Time and Hefty Fine
Last week, on the same day the Supreme Court heard a case that could overturn Roe v. Wade, the landmark ruling on abortion rights, Texas enacted a law that creates criminal penalties for anyone who prescribes medication abortions via telehealth or mail.
-
Journalists Explore Health Care Disparities and Policy Pitfalls
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
Success of Covid Antiviral Pills Hinges on Access to Speedy and Accurate Tests
The promising antiviral drugs to treat covid can halt hospitalizations and deaths, but only if they’re given to patients within three to five days of their first symptoms, a narrow window many people won’t meet. Here’s why.
-
KHN’s ‘What the Health?’: Boosting Confusion
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer’s disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the “An Arm and a Leg” podcast.
-
Perspective
Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
-
As Big Pharma and Hospitals Battle Over Drug Discounts, Patients Miss Out on Millions in Benefits
The number of pharmacies dispensing 340B discounted drugs soared to more than 31,000 this year. Drugmakers struck back by halting some discounts. Hospitals say they are losing millions of dollars — and cutting back services to patients — as a result.